{"id":"W2767287110","doi":"10.1016/s1470-2045(17)30690-3","title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Quality of life (healthcare); Lung cancer; Discontinuation; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical endpoint; Cancer; Clinical trial; Chemotherapy; Progressive disease; Immunotherapy; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003202763,0.0002220029,0.001437351,0.00009252578,0.0002509063,0.00004457532,0.0008987804,0.0001948725,0.0000553449],"category_scores_gemma":[0.002178475,0.0001632216,0.0001659383,0.0001010881,0.000341585,0.0001605008,0.0001154484,0.000322638,0.000005675601],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005239844,"about_ca_system_score_gemma":0.0008059217,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002048178,"about_ca_topic_score_gemma":0.001260886,"domain_scores_codex":[0.997184,0.0004853861,0.001242119,0.0004084145,0.0002307303,0.0004493856],"domain_scores_gemma":[0.9956933,0.00173261,0.001493737,0.0008047617,0.000168627,0.0001069376],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.915262,0.001788072,0.00003328734,0.00004851667,0.0006152205,0.000009041111,0.001637309,0.000003749231,0.001957478,0.0002770084,0.003323325,0.07504494],"study_design_scores_gemma":[0.958053,0.006504026,0.002691539,0.0001928977,0.00005534448,0.000008597883,0.0003035368,0.0004369573,0.0004470435,0.0001267427,0.03101373,0.0001665881],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9116527,0.001061193,0.00009745704,0.06862611,0.002930671,0.006528152,0.0003340748,0.00003470584,0.008734879],"genre_scores_gemma":[0.9901337,0.002504407,0.001387181,0.003781898,0.0007026153,0.0004729541,0.000191144,0.00003619519,0.0007899267],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07848092,"threshold_uncertainty_score":0.6655982,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1861621644064396,"score_gpt":0.4962273689759054,"score_spread":0.3100652045694658,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}